Establishing oncological safety of autologous fat transfer for total breast reconstruction: Results from the multicentre BREAST-I and BREAST-II trials.
van der Venne WBW., Michiels R., van Kuijk SMJ., Tjan-Heijnen VCG., BREAST trial investigators, BREAST-II trial investigators
Cohort Study, published in Eur J Surg Oncol (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Cohort Study
- Journal
- Eur J Surg Oncol (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41643626
- DOI
- 10.1016/j.ejso.2026.111417
Abstract (original English)
Background Autologous fat transfer (AFT) has gained popularity as a minimally invasive alternative for autologous breast reconstruction post-mastectomy. It offers aesthetic advantages and improvements in quality-of-life, though concerns persist regarding its oncological safety due to the presence of adipose-derived stem cells (ADSCs). Methods This pooled follow-up analysis combined data from the multicentre randomised controlled BREAST-I trial and the nonrandomised clinical BREAST-II trial, including women who underwent total breast reconstruction with AFT between 2015 and 2025. The AFT-cohort was compared with a nationwide control group of breast cancer patients derived from the Netherlands Cancer Registry (IKNL), matched by inverse probability weighting. The primary outcome was overall survival (OS). Local and regional recurrences and distant metastases were not included in statistical analyses due to known underreporting in the national registry, but were descriptively assessed within the study cohort. Results A total of 242 AFT-patients and 19936 controls were included. The mean follow-up time was 8.0 years for AFT and 6.9 years for controls. Ten-year crude OS was 97.6 % (95 % CI 95.5-99.7 %) for AFT and 75.7 % (95 % CI 74.7-76.8 %) for controls. After adjustment for confounders and immortal time bias, AFT was not associated with increased mortality (HR 0.34; 95 % CI 0.14-0
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.